Ulf Bömer

2.2k total citations
23 papers, 1.4k citations indexed

About

Ulf Bömer is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Ulf Bömer has authored 23 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 4 papers in Oncology and 3 papers in Cancer Research. Recurrent topics in Ulf Bömer's work include Mitochondrial Function and Pathology (10 papers), RNA and protein synthesis mechanisms (6 papers) and ATP Synthase and ATPases Research (4 papers). Ulf Bömer is often cited by papers focused on Mitochondrial Function and Pathology (10 papers), RNA and protein synthesis mechanisms (6 papers) and ATP Synthase and ATPases Research (4 papers). Ulf Bömer collaborates with scholars based in Germany, France and United States. Ulf Bömer's co-authors include Nikolaus Pfanner, Angelika Hönlinger, Klaus Dietmeier, Oliver von Ahsen, Christoph Eckerskorn, Michael Kübrich, Joachim Rassow, P. Dekker, Bernard Guiard and Fritz Lottspeich and has published in prestigious journals such as Nature, Journal of Biological Chemistry and The EMBO Journal.

In The Last Decade

Ulf Bömer

23 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ulf Bömer Germany 18 1.3k 187 151 85 72 23 1.4k
Yael David United States 21 1.1k 0.9× 188 1.0× 148 1.0× 80 0.9× 97 1.3× 45 1.3k
S. V. Khoronenkova United Kingdom 17 1.0k 0.8× 382 2.0× 65 0.4× 83 1.0× 113 1.6× 29 1.2k
Cynthia S. Collins United States 9 732 0.6× 61 0.3× 72 0.5× 79 0.9× 49 0.7× 11 848
Paul T. Wilder United States 24 1.3k 1.1× 135 0.7× 42 0.3× 48 0.6× 48 0.7× 50 1.5k
Claudio Zambaldo United States 16 899 0.7× 128 0.7× 44 0.3× 71 0.8× 20 0.3× 21 1.1k
Jörg Trappe Switzerland 14 463 0.4× 180 1.0× 45 0.3× 19 0.2× 53 0.7× 15 831
Vangipuram S. Rangan United States 20 716 0.6× 368 2.0× 29 0.2× 39 0.5× 50 0.7× 38 1.2k
Rasmus Ree Norway 10 1.0k 0.8× 567 3.0× 23 0.2× 78 0.9× 120 1.7× 14 1.3k
André Richters Germany 17 480 0.4× 144 0.8× 20 0.1× 57 0.7× 56 0.8× 24 776
Örjan Zetterqvist Sweden 21 1.1k 0.9× 361 1.9× 46 0.3× 193 2.3× 39 0.5× 46 1.5k

Countries citing papers authored by Ulf Bömer

Since Specialization
Citations

This map shows the geographic impact of Ulf Bömer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ulf Bömer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ulf Bömer more than expected).

Fields of papers citing papers by Ulf Bömer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ulf Bömer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ulf Bömer. The network helps show where Ulf Bömer may publish in the future.

Co-authorship network of co-authors of Ulf Bömer

This figure shows the co-authorship network connecting the top 25 collaborators of Ulf Bömer. A scholar is included among the top collaborators of Ulf Bömer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ulf Bömer. Ulf Bömer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lemos, Clara, Volker Schulze, Simon J. Baumgart, et al.. (2021). The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models. Cellular Oncology. 44(3). 581–594. 29 indexed citations
2.
Lücking, Ulrich, Dirk Kosemund, Niels Böhnke, et al.. (2021). Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer. Journal of Medicinal Chemistry. 64(15). 11651–11674. 53 indexed citations
3.
Wengner, Antje M., Gerhard Siemeister, Ulrich Lücking, et al.. (2019). The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models. Molecular Cancer Therapeutics. 19(1). 26–38. 145 indexed citations
4.
Lefranc, Julien, Volker Schulze, R.C. Hillig, et al.. (2019). Discovery of BAY-985, a Highly Selective TBK1/IKKε Inhibitor. Journal of Medicinal Chemistry. 63(2). 601–612. 32 indexed citations
5.
Lemos, Clara, Duy Nguyen, Lars Wortmann, et al.. (2018). Abstract 5866: Discovery and profiling of a highly potent and selective ERK5 inhibitor: BAY-885. Cancer Research. 78(13_Supplement). 5866–5866. 1 indexed citations
6.
Lobell, Mario, Dirk Brohm, Hartmut Schirok, et al.. (2018). Discovery of Rogaratinib (BAY 1163877): a pan‐FGFR Inhibitor. ChemMedChem. 13(5). 437–445. 40 indexed citations
7.
Siegel, Franziska, Antje M. Wengner, Claudia Lange, et al.. (2017). BAY 1143269, a novel MNK1 inhibitor, targets oncogenic protein expression and shows potent anti-tumor activity. Cancer Letters. 390. 21–29. 48 indexed citations
8.
Politz, Oliver, Franziska Siegel, Lars Bärfacker, et al.. (2016). BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling‐dependent tumor growth in mouse models. International Journal of Cancer. 140(2). 449–459. 51 indexed citations
9.
Zopf, Dieter, Maria Kissel, Michael Mamounas, et al.. (2010). 152 The novel highly selective and efficacious MET inhibitor BAY853474: mode of action, basic in vitro characteristics and preclinical pharmacology. European Journal of Cancer Supplements. 8(7). 53–54. 1 indexed citations
10.
Bergsdorf, Christian, et al.. (2006). A Cost-Effective Solution to Reduce Dead Volume of a Standard Dispenser System by a Factor of 5. SLAS DISCOVERY. 11(4). 407–412. 3 indexed citations
11.
Ahsen, Oliver von & Ulf Bömer. (2005). High‐Throughput Screening for Kinase Inhibitors. ChemBioChem. 6(3). 481–490. 112 indexed citations
12.
Geissler, Andreas, Thomas Krimmer, Ulf Bömer, et al.. (2000). Membrane Potential-Driven Protein Import into Mitochondria. Molecular Biology of the Cell. 11(11). 3977–3991. 111 indexed citations
13.
14.
Dietmeier, Klaus, Angelika Hönlinger, Ulf Bömer, et al.. (1997). Tom5 functionally links mitochondrial preprotein receptors to the general import pore. Nature. 388(6638). 195–200. 227 indexed citations
15.
16.
Bömer, Ulf, Michiel Meijer, Bernard Guiard, et al.. (1997). The Sorting Route of Cytochrome b 2Branches from the General Mitochondrial Import Pathway at the Preprotein Translocase of the Inner Membrane. Journal of Biological Chemistry. 272(48). 30439–30446. 35 indexed citations
17.
Bömer, Ulf, Michiel Meijer, Ammy C. Maarse, et al.. (1997). Multiple interactions of components mediating preprotein translocation across the inner mitochondrial membrane. The EMBO Journal. 16(9). 2205–2216. 51 indexed citations
18.
Bömer, Ulf, Nikolaus Pfanner, & Klaus Dietmeier. (1996). Identification of a third yeast mitochondrial Tom protein with tetratrico peptide repeats. FEBS Letters. 382(1-2). 153–158. 46 indexed citations
19.
Bömer, Ulf, Joachim Rassow, Nicole Zufall, et al.. (1996). The Preprotein Translocase of the Inner Mitochondrial Membrane: Evolutionary Conservation of Targeting and Assembly of Tim17. Journal of Molecular Biology. 262(4). 389–395. 51 indexed citations
20.
Gärtner, Frank, Ulf Bömer, Bernard Guiard, & Nikolaus Pfanner. (1995). The sorting signal of cytochrome b2 promotes early divergence from the general mitochondrial import pathway and restricts the unfoldase activity of matrix Hsp70.. The EMBO Journal. 14(23). 6043–6057. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yael David Breakdown of academic impact, for papers by S. V. Khoronenkova Breakdown of academic impact, for papers by Cynthia S. Collins Breakdown of academic impact, for papers by Paul T. Wilder Breakdown of academic impact, for papers by Claudio Zambaldo Breakdown of academic impact, for papers by Jörg Trappe Breakdown of academic impact, for papers by Vangipuram S. Rangan Breakdown of academic impact, for papers by Rasmus Ree Breakdown of academic impact, for papers by André Richters Breakdown of academic impact, for papers by Örjan Zetterqvist
Rankless by CCL
2026